Skip to main content

Breast Cancer

Featured Article
Compared with those with private insurance, participants in breast cancer clinical trials with Medicare, Medicaid, or other government insurance were less likely to complete trials and had a lower…
Most clinical trials supporting US Food and Drug Administration approval of drugs for metastatic breast cancer over the past 13 years did not meet thresholds for substantial clinical benefit on two…

Interactive Features

In an exclusive interview at SABCS 2019, Dawn Hershman, MD, MS, professor of medicine and epidemiology at Columbia University Medical Center, Herbert Irving Comprehensive Cancer Center, discusses how the cost of breast cancer treatment is directly…
“From a payer's perspective, this is a mechanism to address the dramatically rising cost of cancer care in a way that not only reduces costs, but also improves quality at the same time,” explained Charles Saunders, MD, chief executive office,…
Back to Top